Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. More Details
Very undervalued with limited growth.
Share Price & News
How has Amneal Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AMRX's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AMRX underperformed the US Pharmaceuticals industry which returned 3.7% over the past year.
Return vs Market: AMRX underperformed the US Market which returned 19.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Amneal Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StThese 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
1 month ago | Simply Wall StAre Amneal Pharmaceuticals's (NYSE:AMRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?
2 months ago | Simply Wall StHere's What Analysts Are Forecasting For Amneal Pharmaceuticals, Inc. (NYSE:AMRX) After Its Third-Quarter Results
Is Amneal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRX ($4.83) is trading below our estimate of fair value ($9.9)
Significantly Below Fair Value: AMRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRX is good value based on its PE Ratio (11.4x) compared to the US Pharmaceuticals industry average (24.1x).
PE vs Market: AMRX is good value based on its PE Ratio (11.4x) compared to the US market (21x).
Price to Earnings Growth Ratio
PEG Ratio: AMRX is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: AMRX is good value based on its PB Ratio (2.4x) compared to the US Pharmaceuticals industry average (4.4x).
How is Amneal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRX's forecast earnings growth (13.3% per year) is above the savings rate (2%).
Earnings vs Market: AMRX's earnings (13.3% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: AMRX's earnings are forecast to grow, but not significantly.
Revenue vs Market: AMRX's revenue (2% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: AMRX's revenue (2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRX's Return on Equity is forecast to be very high in 3 years time (51.3%).
How has Amneal Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRX has a large one-off loss of $293.8M impacting its September 30 2020 financial results.
Growing Profit Margin: AMRX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AMRX's earnings have declined by 63.3% per year over the past 5 years.
Accelerating Growth: AMRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AMRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: AMRX's Return on Equity (3%) is considered low.
How is Amneal Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AMRX's short term assets ($1.5B) exceed its short term liabilities ($667.9M).
Long Term Liabilities: AMRX's short term assets ($1.5B) do not cover its long term liabilities ($3.0B).
Debt to Equity History and Analysis
Debt Level: AMRX's debt to equity ratio (800.2%) is considered high.
Reducing Debt: Insufficient data to determine if AMRX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: AMRX's debt is not well covered by operating cash flow (7.7%).
Interest Coverage: AMRX's interest payments on its debt are not well covered by EBIT (1x coverage).
What is Amneal Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: AMRX is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chirag Patel (53 yo)
Mr. Chirag K. Patel has been Co-Chief Executive Officer and President of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as Director an...
|Executive VP & Chief Commercial Officer of Generics||2.92yrs||US$3.11m||0.074% |
|Executive VP & CFO||0.83yr||no data||no data|
|Senior VP||1yr||no data||no data|
|Executive Vice President of Sales & Marketing||no data||no data||no data|
|Executive VP and Chief Human Resources Officer & Strategic Planning Officer||7yrs||US$1.54m||0.12% |
|Senior Vice President of Operations||no data||no data||no data|
|Senior Vice President of Regulatory Affairs||no data||no data||no data|
|Executive VP & Chief Commercial Officer of Specialty||2.67yrs||no data||0.17% |
|Head of Ops & Executive VP of Amneal Pharmaceuticals (India) Pvt Ltd||no data||no data||no data|
|President of India Operations||2yrs||no data||no data|
Experienced Management: AMRX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|Chairman & MD of Amneal Pharmaceuticals (India) Pvt Ltd||no data||no data||no data|
|Independent Chairman of the Board||1.42yrs||US$305.77k||0.26% |
|Independent Director||2.67yrs||US$390.26k||0.016% |
|Independent Director||2.67yrs||US$379.23k||0.042% |
|Independent Director||1.08yrs||US$112.16k||0.0051% |
|Director||no data||no data||no data|
|Independent Director||1.08yrs||US$112.16k||0.021% |
|Independent Director||1.08yrs||US$112.16k||0.012% |
Experienced Board: AMRX's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Amneal Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Amneal Pharmaceuticals, Inc.
- Ticker: AMRX
- Exchange: NYSE
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.448b
- Market Cap: US$713.045m
- Shares outstanding: 299.75m
- Website: https://www.amneal.com
Number of Employees
- Amneal Pharmaceuticals, Inc.
- 400 Crossing Boulevard
- 3rd Floor
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AMRX||NYSE (New York Stock Exchange)||Yes||Class A Common Shares||US||USD||May 2018|
|2DT||DB (Deutsche Boerse AG)||Yes||Class A Common Shares||DE||EUR||May 2018|
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeut...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 23:42|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.